SCHEMBL2151647

SCHEMBL2151647

O=C(O)C12CC1CCCCCCCCCN1CCCC1CN2

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HTR6 P50406 1/20 0.39
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ HRH3 Q9Y5N1 2/20 0.34
▸ KCNH2 Q12809 1/20 0.34
▸ KDM4E B2RXH2 4/20 0.33
▸ POLB P06746 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ L3MBTL3 Q96JM7 2/20 0.33
▸ L3MBTL1 Q9Y468 2/20 0.33
▸ GAA P10253 1/20 0.33
▸ SIGMAR1 Q99720 3/20 0.32
▸ CHRM5 P08912 2/20 0.32
▸ CHRM1 P11229 2/20 0.32
▸ CHRM2 P08172 1/20 0.32
▸ CHRM4 P08173 1/20 0.32
▸ CHRM3 P20309 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2151722 0.99 HTR6 (0.38) HTR6MEN1KMT2AHRH3KCNH2
Diethylamine SCHEMBL2151568 0.90 MEN1 (0.33) HTR6MEN1KMT2AKDM4EALDH1A1
SCHEMBL2009518 0.87 HTR6 (0.38) HTR6MEN1KMT2AHRH3KCNH2
Hydrochloric Acid SCHEMBL3696745 0.86 HTR6 (0.37) HTR6MEN1KMT2AHRH3KCNH2
SCHEMBL7316779 0.69 SLC6A1 (0.32) MEN1KMT2A
SCHEMBL16058143 0.69 SLC6A1 (0.32) MEN1KMT2A
Bicarbonate SCHEMBL11101479 0.68 L3MBTL3 (0.50) MEN1KMT2AKDM4EPOLBALDH1A1
Bicarbonate SCHEMBL19689366 0.68 L3MBTL3 (0.50) MEN1KMT2AKDM4EPOLBALDH1A1
SCHEMBL2012120 0.68 L3MBTL3 (0.31) HTR6L3MBTL3L3MBTL1
Hydrochloric Acid SCHEMBL23495001 0.68 SLC6A1 (0.31) MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2909205-A1 HEPATITIS C VIRUS INHIBITORS Bristol-Myers Squibb Company (US) 2015-08-26 — — EP disclosed
WO-2014062196-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2014-04-24 — — WO disclosed
EP-2705049-A1 HEPATITIS C VIRUS INHIBITORS Bristol-Myers Squibb Company (US) 2014-03-12 — — EP disclosed
EP-2658858-A2 PHENANTHRIDINE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS Enanta Pharmaceuticals, Inc. (US) 2013-11-06 — — EP disclosed
EP-2576564-A2 MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS Abbvie Inc. (US) 2013-04-10 — — EP disclosed
WO-2012151195-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2012-11-08 — — WO disclosed
WO-2012092411-A2 PHENANTHRIDINE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS ENANTA PHARMACEUTICALS, INC. (US) 2012-07-05 — — WO disclosed
WO-2011156337-A2 MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS ABBOTT LABORATORIES (US) 2011-12-15 — — WO disclosed
WO-2011150190-A2 HCV INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF ANACOR PHARMACEUTICALS, INC. (US) 2011-12-01 — — WO disclosed
EP-2340029-A2 MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS Enanta Pharmaceuticals, Inc. (US) 2011-07-06 — — EP disclosed
WO-2010030359-A2 MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS ENANTA PHARJMACEUTICALS, INC. (US) 2010-03-18 — — WO disclosed
EP-1805187-A1 INHIBITORS OF HEPATITIS C VIRUS PROTEASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME Pfizer, Inc. (US) 2007-07-11 — — EP disclosed
WO-2006043145-A1 INHIBITORS OF HEPATITIS C VIRUS PROTEASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME PFIZER INC. (US) 2006-04-27 — — WO disclosed
Send feedback